Blood Platelets, Aspirin and Prevention of Vascular Disease
“In 40 years as a general practitioner, I have been especially interested in the possibility that some simple and harmless agent may be effective against the two major causes of death and disability among the persons who have most to contribute to our civilization. When aspirin appeared to offer such protection, I urged my friends and patients to adopt the practice of taking aspirin, one or two 5 gr. tablets daily. Surely the practice could do no harm. It might prove life-saving. To date, approximately 8,000 men have adopted this regime, with a surprising result. Not a single case of detectable coronary or cerebral thrombosis has occurred among patients who faithfully have adhered to this regime. Sufficient time has elapsed since the start of this program for me to report that aspirin administration offers a safe and sure method of prophylaxis against thrombosis” (Craven, 1956).
Unable to display preview. Download preview PDF.
- Buczko W, de Gaetano G, Franco R, Donati MB. Biological properties of dialysable peptides derived from plasmin digestion of bovine fibrinogen preparations. Thromb Diath Haemorrh 1976; 35: 651–657.Google Scholar
- Craven LL. Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Mississippi Valley Med J 1956; 75: 38–44.Google Scholar
- ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,189 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349–360. •Google Scholar
- Moroz LA. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med 1977; 296:525.Google Scholar
- O’ Brien JR. Effects of salicylates on human platelets. Lancet 1968; i:779–83.Google Scholar
- Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Nati Acad Sci USA1975; 72: 3073–76.Google Scholar